Delcath Systems, Inc. (NASDAQ:DCTH) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Delcath Systems, Inc. (NASDAQ:DCTH) have been given an average recommendation of “Moderate Buy” by the six research firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $22.50.

A number of equities analysts have recently commented on DCTH shares. Wall Street Zen downgraded Delcath Systems from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Evercore set a $27.00 price objective on shares of Delcath Systems in a research report on Thursday, February 26th. Weiss Ratings restated a “sell (d+)” rating on shares of Delcath Systems in a research note on Monday, December 29th. BTIG Research reduced their price target on Delcath Systems from $23.00 to $19.00 and set a “buy” rating on the stock in a research report on Thursday, February 26th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Delcath Systems in a research report on Friday, January 9th.

Delcath Systems Price Performance

Shares of DCTH opened at $9.08 on Monday. Delcath Systems has a fifty-two week low of $8.12 and a fifty-two week high of $18.23. The company’s fifty day moving average is $9.86 and its two-hundred day moving average is $10.14. The firm has a market cap of $315.53 million, a PE ratio of 129.71 and a beta of 0.38.

Delcath Systems (NASDAQ:DCTH) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01. The business had revenue of $20.73 million during the quarter, compared to the consensus estimate of $20.35 million. Delcath Systems had a return on equity of 2.63% and a net margin of 3.17%. As a group, equities research analysts anticipate that Delcath Systems will post -0.79 earnings per share for the current year.

Delcath Systems declared that its board has approved a share repurchase program on Thursday, November 20th that permits the company to buyback $25.00 million in outstanding shares. This buyback authorization permits the company to repurchase up to 8.6% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s management believes its stock is undervalued.

Institutional Investors Weigh In On Delcath Systems

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Rosalind Advisors Inc. boosted its position in Delcath Systems by 13.8% in the 2nd quarter. Rosalind Advisors Inc. now owns 3,300,389 shares of the company’s stock valued at $44,885,000 after buying an additional 400,000 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Delcath Systems by 2.9% during the third quarter. Vanguard Group Inc. now owns 1,657,428 shares of the company’s stock valued at $17,817,000 after acquiring an additional 46,693 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Delcath Systems by 128.1% during the second quarter. Geode Capital Management LLC now owns 703,171 shares of the company’s stock worth $9,565,000 after acquiring an additional 394,902 shares during the last quarter. Nantahala Capital Management LLC purchased a new stake in shares of Delcath Systems during the third quarter worth about $7,164,000. Finally, Goldman Sachs Group Inc. lifted its stake in shares of Delcath Systems by 116.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 587,678 shares of the company’s stock worth $5,936,000 after acquiring an additional 315,583 shares in the last quarter. Hedge funds and other institutional investors own 61.12% of the company’s stock.

Delcath Systems Company Profile

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.